Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

The promise of help with weight loss ... GLP-1 drugs can lower the risk of: - Stroke and heart attacks. - Substance use disorders. - Seizures. - Dementia and Alzheimer’s disease. For diabetics ...

HUNTINGTON — GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza and Wegovy started as a way to treat diabetes but have since become popular tools for weight loss. Dr. Matthew Christiansen ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

Embarking on the quest to lose weight can be a risky business. Yo-yo dieting, compulsive binging, muscle wasting and brain ...